about
Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.Building Data-Driven Pathways From Routinely Collected Hospital Data: A Case Study on Prostate CancerCosts of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysisActive surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1.Cost of illness of the prostate cancer in Japan--a time-trend analysis and future projections.Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancerCancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability.Inorganic Arsenic-Related Changes in the Stromal Tumor Microenvironment in a Prostate Cancer Cell-Conditioned Media Model.Maternal high-fat diet induces hyperproliferation and alters Pten/Akt signaling in prostates of offspring.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.The link between benign prostatic hyperplasia and prostate cancer.Management of cancer treatment-induced bone loss.Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.An introduction to acinar pressures in BPH and prostate cancer.Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application.Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis.Cost-of-illness studies in chronic ulcers: a systematic review.The Metabolic Phenotype of Prostate Cancer.Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis.Habitual Tea Consumption Reduces Prostate Cancer Risk in Vietnamese Men: a Case-Control StudyGeographical Factors Associated With Health Disparities in Prostate Cancer.[Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].The economic burden of cancer in the UK: a study of survivors treated with curative intent.[Economic importance of postoperative urinary incontinence].Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy developmentAndrogen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients.Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.MiR-26a inhibits prostate cancer progression by repression of Wnt5a.Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways
P2860
Q30912685-6578F6CA-47FE-45EF-B504-4F1D4A6C0EA0Q30979644-6B4F104A-8692-425F-9DA7-1A7E83B4D69DQ31143305-3AD358BC-B381-4C1E-A176-060604AD0CD3Q33855285-67CB00BC-B74F-45C6-AD02-7EB2AD04454FQ34430173-EEE56E47-B0BD-440D-8552-C45607DAA912Q35799949-60C043AD-24CE-4D7C-9717-F52DE7B71416Q35919544-D3F17544-9F34-40F6-9BCF-D809B86D9F4FQ36177951-3376FD5A-8526-4B69-B82E-EA101012471BQ36897614-C7949250-4443-4DA6-ACF4-867592A89B77Q37003341-4E1672CE-0BBE-4513-8891-4CFA3651D62EQ37077753-C5D79132-DA78-4B70-8915-A423E530236CQ37379265-95366367-94F1-44F2-B8C2-0B309551F294Q38013964-FD70CA66-D19F-4FA5-8913-E07C6AC8CB31Q38061029-329BC858-CA28-4DA4-A7CD-7387D6F60865Q38090917-792EA8A4-A85B-4C89-A432-FDCA11D13DA2Q38092015-7AD6B2CC-5558-4A1A-B05D-D472F51CAD97Q38106624-F4038C1A-9842-4418-8533-19CF94FDA7EAQ38139567-0EE9AAB2-ABDD-4856-B75D-B1D74203E8A1Q38747617-34A4091A-5101-44BF-B8F5-56189D531589Q38995570-52E03950-0603-40AF-A090-E7DADC057364Q39221460-4C2A881B-7D1E-46E0-BEB6-991E9F9BCED8Q39412872-ABD8E1CB-B3D1-4684-99FC-2E554DB5F8B4Q39469118-3D0760FD-10FC-48C4-AA66-71EC31631AC8Q40403392-CBBB6285-62AB-44DB-BFDD-A8E219ECDF8BQ40476413-61628FC9-8DCF-4032-9343-3BE09828091EQ40485174-C865D147-832A-4361-8EDB-85F338C0A86CQ40823428-5A6CA7F0-3290-41A6-A060-B66F97808AFBQ41329187-7EF4ACBC-286D-46FC-BCFD-043ECAA69096Q41388484-1B8382C5-8F08-4AB4-8B5F-F16B748771CFQ41450346-A0975A10-527C-4B14-9D8B-D4E0EC1E6784Q41674349-AC709689-6DA4-45D6-8002-DED3A63B9EEAQ41915850-277EEF0C-6A9F-43A1-B966-F8245DB40041Q42315786-1C75B6C7-4092-463F-9504-DC7E5B526AFFQ49466230-45458A30-0F88-46B6-999E-A6F3B7FEE64AQ54200488-B90CA690-2F88-49DD-A3C8-F0653E4F6107Q58562101-D9AFC2CA-279A-432F-97FC-0DBBE04D65BB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The economic burden of prostate cancer.
@en
The economic burden of prostate cancer.
@nl
type
label
The economic burden of prostate cancer.
@en
The economic burden of prostate cancer.
@nl
prefLabel
The economic burden of prostate cancer.
@en
The economic burden of prostate cancer.
@nl
P2860
P1433
P1476
The economic burden of prostate cancer.
@en
P2093
Claus G Roehrborn
Libby K Black
P2860
P304
P356
10.1111/J.1464-410X.2011.10365.X
P577
2011-09-01T00:00:00Z